Reductions in glucose among postmenopausal women who use and do not use estrogen therapy
Catherine Kim, Shengchun Kong, Gail A. Laughlin et al. · Menopause The Journal of The North American Menopause Society · 2012
OBJECTIVE: Among postmenopausal women who do not use estrogen therapy (ET), we have previously reported that intensive lifestyle modification (ILS) leads to increases in sex hormone-binding globulin (SHBG) and that such increases are associated with reductions in fasting plasma glucose (FPG) and 2-hour postchallenge glucose (2HG). Oral ET decreases FPG and increases 2HG while increasing both SHBG and estradiol (E2). It is unknown if ILS reduces glucose among ET users, if changes in SHBG and E2 might mediate any glucose decreases in ET users, and if these patterns differ from those in non-ET users. METHODS: We conducted a secondary analysis of postmenopausal women in the Diabetes Prevention Program who used ET at baseline and 1-year follow-up (n = 324) and who did not use ET at either time point (n = 382). Participants were randomized to ILS, metformin, or placebo administered at 850 mg BID. RESULTS: ET users were younger, more often white, and more likely to have had bilateral oophorectomy than non-ET users. Among ET users, ILS reduced FPG (P < 0.01) and 2HG (P < 0.01), and metformin reduced FPG (P < 0.01) but not 2HG (P = 0.56), compared with placebo. Associations between SHBG and total E2 with FPG and 2HG were not significant among women randomized to ILS or metformin. These patterns differed from those observed among women who did not use ET. CONCLUSIONS: We conclude that among glucose-intolerant ET users, interventions to reduce glucose are effective but possibly mediated through different pathways than among women who do not use ET.
Cited by 23 works. doi:10.1097/gme.0b013e3182703b73
Authors
- Catherine Kim
- Shengchun Kong
- Gail A. Laughlin
- Sherita Hill Golden
- Kieren J. Mather
- Bin Nan
- John F. Randolph
- Sharon L. Edelstein
- Fernand Labrie
- Elizabeth Buschur
- Elizabeth Barrett‐Connor
References
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
- Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperature
- Effect of Weight Loss With Lifestyle Intervention on Risk of Diabetes
- Glycemic Effects of Postmenopausal Hormone Therapy: The Heart and Estrogen/progestin Replacement Study: A Randomized, Double-Blind, Placebo-Controlled Trial
- Endogenous Sex Hormones and the Development of Type 2 Diabetes in Older Men and Women: the Rancho Bernardo Study
- Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program
- The Influence of Age on the Effects of Lifestyle Modification and Metformin in Prevention of Diabetes
- Effect of Postmenopausal Hormone Therapy on Glucose and Insulin Concentrations
- Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program